Trinitrophenol

Trinitrophenol

SCHEMBL1134872

O=C(O)CNC(=O)c1ccccc1.O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TRPA1TRPV4

The experimentally established mechanism targets of Trinitrophenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.51
ALDH1A1 P00352 3/20 0.47
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 2/20 0.47
TAAR1 Q96RJ0 1/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
PKM P14618 1/20 0.46
CES2 O00748 1/20 0.46
MITF O75030 1/20 0.46
POLB P06746 1/20 0.46
KDM4E B2RXH2 1/20 0.45
TTR P02766 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1134873 0.80 RAB9A (0.58) RAB9AALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL6777037 0.79 ALDH1A1 (0.67) RAB9AALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL11340446 0.78 PKM (0.56) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL11025520 0.78 LMNA (0.56) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL1285585 0.78 NPC1 (0.61) RAB9AALDH1A1SMN1; SMN2NPC1TAAR1
SCHEMBL22030672 0.76 GAA (0.68) RAB9ASMN1; SMN2NPC1MAPTLMNA
Hippuric Acid SCHEMBL7486 0.76 GAA (0.68) RAB9ASMN1; SMN2NPC1MAPTLMNA
Hippuric Acid SCHEMBL428479 0.76 GAA (0.68) RAB9ASMN1; SMN2NPC1MAPTLMNA
Trinitrophenol SCHEMBL31588669 0.76 GPR35 (0.73) ALDH1A1HPGDSMN1; SMN2CRHBPCRHR2
SCHEMBL15610402 0.75 LMNA (0.56) RAB9AALDH1A1HPGDSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3083628-B1 FUSED IMIDAZOLYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS ESTEVE PHARMACEUTICALS SA (ES) 2019-08-07 EP disclosed
EP-2817309-B1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES, THEIR PREPARATION AND USE AS MEDICAMENTS ESTEVE LABOR DR (ES) 2018-06-20 EP disclosed
US-9789117-B2 Use of sigma ligands in diabetes type-2 associated pain LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2017-10-17 US disclosed
EP-1781272-B1 USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA ESTEVE LABOR DR (ES) 2017-09-06 EP disclosed
CN-104254535-B Substituted pyrazolo [1,5 a] pyridine, its prepare and be used as the application of medicine 埃斯蒂文博士实验室股份有限公司 2017-07-14 CN disclosed
US-9676784-B2 Fused imidazolyl derivatives, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2017-06-13 US disclosed
EP-2066648-B1 SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS ESTEVE LABOR DR (ES) 2017-04-12 EP disclosed
US-9617281-B2 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments LABORATORIES DEL DR. ESTEVE S.A. (ES) 2017-04-11 US disclosed
EP-2986616-B1 TRICYCLIC TRIAZOLIC COMPOUNDS AS SIGMA RECEPTORS LIGANS ESTEVE LABOR DR (ES) 2017-03-29 EP disclosed
EP-2807169-B1 SUBSTITUTED PYRANO AND FURANOQUINOLINES, THEIR PREPARATION AND USE AS MEDICAMENTS ESTEVE LABOR DR (ES) 2017-03-01 EP disclosed
WO-2006069807-A1 SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-07-06 WO disclosed
WO-2006069806-A1 PHARMACEUTICAL COMPOSITION COMPRINSING A 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS, A POTASSIUM ION CHANNEL MODULATOR AND A PHOSPHODIESTERASE TYPE 5 INHIBITOR LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-07-06 WO disclosed
WO-2006069809-A1 SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-07-06 WO disclosed
EP-1676841-A1 Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments Esteve Laboratorios Dr. Esteve S.A. (ES) 2006-07-05 EP disclosed
EP-1676573-A1 Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-07-05 EP disclosed
EP-1676842-A1 Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-07-05 EP disclosed
EP-1652521-A1 Pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-05-03 EP disclosed
WO-2006010587-A1 USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-02-02 WO disclosed
US-20060019969-A1 Use of compounds active on the sigma receptor for the treatment of allodynia LABORATORIOS DR. ESTEVE S.A. (ES) 2006-01-26 US disclosed
US-20060019968-A1 Use of compounds active on the sigma receptor for the treatment of neuropathic pain LABORATORIOS DR. ESTEVE S.A. (ES) 2006-01-26 US disclosed